|
BC-P007
|
4 × 104
|
2 × 104
|
1 × 104
|
5 × 103
|
4 × 103
|
1 × 103
|
500
|
100
|
50
|
20
|
Frequency〒
|
Distribution#
|
|---|
|
ALDH+
| |
3/8
| | |
3/8
|
1/3
|
1/7
| | | |
1:2.0 × 104
|
75%
|
|
ALDH-
| |
0/4
| | |
0/6
|
1/7
|
0/3
|
0/4
| | |
1:1.1 × 105
|
25%
|
|
ALDH+/GD2+
| |
2/2
| | |
3/3
|
6/10
| |
5/10
|
2/20
|
0/3
|
1:6.1 × 102
| |
|
ALDH-/GD2-
|
0/4
| |
0/1
|
0/8
|
2/10
|
0/15
| | | | |
1:1.3 × 105
| |
|
ALDH+
| |
3/8
| | |
3/8
|
1/3
|
1/7
| | | |
1:2.0 × 104
| |
|
ALDH+/GD2+
| |
2/2
| | |
3/3
|
6/10
| |
5/10
|
2/20
|
0/3
|
1:6.1 × 102
| |
|
BC-P515
|
1 × 10
5
|
2 × 10
4
|
1 × 10
4
| |
4 × 10
3
|
1 × 10
3
|
500
|
100
| |
50
|
Frequency
〒
|
Distribution
#
|
|
ALDH+
| |
1/4
|
0/3
| |
1/4
|
3/9
| |
1/5
| | |
1:2.0 × 104
|
96%
|
|
ALDH-
| |
0/4
|
0/3
| |
0/2
|
0/9
| | | | |
1:>4.2 × 105
|
4%
|
|
ALDH+/GD2+
| |
1/3*
|
7/10
| | |
4/5
|
0/1
|
2/7
| |
1/2
|
1:7.1 × 103
| |
|
ALDH-/GD2-
|
0/1
|
0/2
|
1/9
| |
0/4
|
0/10
| | | | |
1:2.5 × 105
| |
|
ALDH+
| |
1/4
|
0/3
| |
1/4
|
3/9
| |
1/5
| | |
1:2.0 × 104
| |
|
ALDH+/GD2+
| |
1/3
|
7/10
| | |
4/5
|
0/1
|
2/7
| |
1/2
|
1:7.1 × 103
| |
- BC-P007 and BC-P515 cryopreserved tumor cells from patient-derived xenografts of PT were sorted by FACS into ALDEFLUOR-positive, ALDEFLUOR-negative or ALDEFLUOR and GD2 double positive and double negative cells. Varying numbers of the sorted cells were injected in fat pads of NOD-SDID mice to evaluate their tumor-initiating potential. The frequency of cancer-initiating cells was analyzed using ELDA software.
- *:Including one of three mice died the day after tumor injection.
- #:The distribution of tumor-initiating cells among the BC-P007 and BC-P515 ALDH + and ALDH- cells.
- 〒:Frequency was calculated by ELDA software, although the P-value for likelihood ratio test of single-hit model in each group was less than P = 0.5.
